Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say

News of the Federal Trade Commission (FTC) lawsuit challenging Amgen’s $28 billion buyout of Horizon prompted an immediate question: Will the U.S. antitrust enforcer also attempt to derail Pfizer’s plan to acquire Seagen for $43 billion?